BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12145750)

  • 1. BRCA2 T2722R is a deleterious allele that causes exon skipping.
    Fackenthal JD; Cartegni L; Krainer AR; Olopade OI
    Am J Hum Genet; 2002 Sep; 71(3):625-31. PubMed ID: 12145750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
    Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
    J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene.
    Aretz S; Uhlhaas S; Sun Y; Pagenstecher C; Mangold E; Caspari R; Möslein G; Schulmann K; Propping P; Friedl W
    Hum Mutat; 2004 Nov; 24(5):370-80. PubMed ID: 15459959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
    Fraile-Bethencourt E; Díez-Gómez B; Velásquez-Zapata V; Acedo A; Sanz DJ; Velasco EA
    PLoS Genet; 2017 Mar; 13(3):e1006691. PubMed ID: 28339459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts.
    Gutiérrez-Enríquez S; Coderch V; Masas M; Balmaña J; Diez O
    Breast Cancer Res Treat; 2009 Sep; 117(2):461-5. PubMed ID: 18712473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.
    Sharp A; Pichert G; Lucassen A; Eccles D
    Hum Mutat; 2004 Sep; 24(3):272. PubMed ID: 15300854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
    Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
    BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sequence variants of BRCA2 exon 7 alter splicing regulation.
    Gaildrat P; Krieger S; Di Giacomo D; Abdat J; Révillion F; Caputo S; Vaur D; Jamard E; Bohers E; Ledemeney D; Peyrat JP; Houdayer C; Rouleau E; Lidereau R; Frébourg T; Hardouin A; Tosi M; Martins A
    J Med Genet; 2012 Oct; 49(10):609-17. PubMed ID: 22962691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA-based analysis of BRCA1 and BRCA2 gene alterations.
    Bonatti F; Pepe C; Tancredi M; Lombardi G; Aretini P; Sensi E; Falaschi E; Cipollini G; Bevilacqua G; Caligo MA
    Cancer Genet Cytogenet; 2006 Oct; 170(2):93-101. PubMed ID: 17011978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes.
    Théry JC; Krieger S; Gaildrat P; Révillion F; Buisine MP; Killian A; Duponchel C; Rousselin A; Vaur D; Peyrat JP; Berthet P; Frébourg T; Martins A; Hardouin A; Tosi M
    Eur J Hum Genet; 2011 Oct; 19(10):1052-8. PubMed ID: 21673748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
    Valarmathi MT; Sawhney M; Deo SSV; Shukla NK; Das SN
    Hum Mutat; 2004 Feb; 23(2):205. PubMed ID: 14722926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
    Zhang L; Bacares R; Boyar S; Hudis C; Nafa K; Offit K
    Mutat Res; 2009 Apr; 663(1-2):84-9. PubMed ID: 19070627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.
    Steffensen AY; Jønson L; Ejlertsen B; Gerdes AM; Nielsen FC; Hansen TV
    Fam Cancer; 2010 Sep; 9(3):283-7. PubMed ID: 20455026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1.
    Zatkova A; Messiaen L; Vandenbroucke I; Wieser R; Fonatsch C; Krainer AR; Wimmer K
    Hum Mutat; 2004 Dec; 24(6):491-501. PubMed ID: 15523642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A missense mutation in exon 13 in BRCA2, c.7235G>A, results in skipping of exon 13.
    Thomassen M; Kruse TA; Jensen PK; Gerdes AM
    Genet Test; 2006; 10(2):116-20. PubMed ID: 16792514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer.
    Nielsen KB; Sørensen S; Cartegni L; Corydon TJ; Doktor TK; Schroeder LD; Reinert LS; Elpeleg O; Krainer AR; Gregersen N; Kjems J; Andresen BS
    Am J Hum Genet; 2007 Mar; 80(3):416-32. PubMed ID: 17273963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11.
    Baert A; Machackova E; Coene I; Cremin C; Turner K; Portigal-Todd C; Asrat MJ; Nuk J; Mindlin A; Young S; MacMillan A; Van Maerken T; Trbusek M; McKinnon W; Wood ME; Foulkes WD; Santamariña M; de la Hoya M; Foretova L; Poppe B; Vral A; Rosseel T; De Leeneer K; Vega A; Claes KBM
    Hum Mutat; 2018 Apr; 39(4):515-526. PubMed ID: 29280214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of disease-associated HRPT2 mutations on splicing.
    Hahn MA; McDonnell J; Marsh DJ
    J Endocrinol; 2009 Jun; 201(3):387-96. PubMed ID: 19332451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations.
    Gambino G; Tancredi M; Falaschi E; Aretini P; Caligo MA
    Int J Mol Med; 2015 Apr; 35(4):950-6. PubMed ID: 25683334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.